ImmuPharma plc (LON:IMM – Get Free Report) shares were up 83.3% during mid-day trading on Thursday . The stock traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.20 ($0.03). Approximately 33,956,879 shares traded hands during trading, an increase of 417% from the average daily volume of 6,568,868 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Performance
The stock has a market cap of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The company has a 50 day moving average of GBX 1.40 and a 200-day moving average of GBX 1.65.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- How to Use the MarketBeat Dividend Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
